145P Neoadjuvant chemotherapy combined with camrelizumab for locally advanced head and neck squamous cell carcinoma: A phase II trial

Stand treatment for head and neck squamous cell carcinoma (HNSCC) includes surgery, chemotherapy, and radiotherapy, which can lead to poor cosmetic and functional outcomes. PD-1 inhibitors have been tested in the neoadjuvant setting for HNSCC, which has the potential to reduce the tumor size, and lead to more limited surgery and better quality of life. This phase 2 trial investigated neoadjuvant chemotherapy combined with PD-1 inhibitor camrelizumab in patients with locally advanced HNSCC.